Pacira BioSciences Target of Unusually Large Options Trading (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) saw some unusual options trading activity on Tuesday. Investors bought 5,734 put options on the company. This is an increase of 1,898% compared to the average volume of 287 put options.

Insider Buying and Selling at Pacira BioSciences

In other news, COO Daryl Gaugler sold 1,000 shares of Pacira BioSciences stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total transaction of $28,380.00. Following the completion of the sale, the chief operating officer now directly owns 116,040 shares of the company’s stock, valued at approximately $3,293,215.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Pacira BioSciences news, insider Kristen Williams sold 7,452 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total value of $211,487.76. Following the transaction, the insider now directly owns 102,912 shares in the company, valued at $2,920,642.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daryl Gaugler sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total transaction of $28,380.00. Following the sale, the chief operating officer now directly owns 116,040 shares in the company, valued at approximately $3,293,215.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,314 shares of company stock valued at $522,053. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds have recently added to or reduced their stakes in PCRX. ICA Group Wealth Management LLC acquired a new position in Pacira BioSciences during the 4th quarter worth approximately $30,000. Quadrant Capital Group LLC boosted its stake in shares of Pacira BioSciences by 61.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock valued at $78,000 after buying an additional 885 shares in the last quarter. Natixis acquired a new position in Pacira BioSciences during the first quarter worth $95,000. Cape Investment Advisory Inc. purchased a new position in Pacira BioSciences in the fourth quarter worth $97,000. Finally, SG Americas Securities LLC acquired a new stake in Pacira BioSciences in the first quarter valued at $106,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on PCRX. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $45.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Barclays decreased their target price on Pacira BioSciences from $40.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. started coverage on Pacira BioSciences in a research note on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective for the company. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $47.40.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock traded down $6.93 during trading hours on Tuesday, hitting $21.53. 5,199,188 shares of the company were exchanged, compared to its average volume of 671,486. The company has a current ratio of 5.81, a quick ratio of 4.78 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average of $28.77 and a 200-day moving average of $29.84. Pacira BioSciences has a 1 year low of $20.52 and a 1 year high of $40.45. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of 16.10 and a beta of 0.88.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The firm had revenue of $167.12 million for the quarter, compared to analysts’ expectations of $165.43 million. Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. As a group, analysts expect that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.